ICARIA met the primary endpoint of prolonging progression free survival in patients treated with isatuximab in combination with pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone alone (standard of care).
Results will be submitted to an upcoming medical meeting and are anticipated to form the basis of regulatory submissions planned for later this year.
"There is a continuing need for new therapeutic options for multiple myeloma in patients who have either relapsed or are no longer responding to their current treatment. The ICARIA study confirms that the investigational agent, isatuximab, in combination with the current standard of care, pomalidomide, improves outcomes for these patients and I'm excited about how these data demonstrate the ability of this investigational compound to extend disease free life in patients living with relapsed/refractory multiple myeloma," Professor Kwee Yong, UK ICARIA Trial Investigator and Professor of Hematology at University College London Hospital said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Multiple myeloma is the second most common haematologic cancer, with approximately more than 5,500 people diagnosed each year in the UK at any one time, it is estimated that 17,500 people are living with this condition. Multiple myeloma remains incurable in the vast majority of patients, resulting in significant disease burden.
"There is an unmet need in the management of relapsed/refractory multiple myeloma and the ICARIA data represents a significant milestone for Sanofi Genzyme and our oncology portfolio,” Dr. Marc Moodley, Medical Director for Sanofi Genzyme said. “The isatuximab development program continues to progress and we are committed to bringing this investigational compound forward as a potential new therapeutic option for patients as soon as possible."
The randomized, multi-center, open label Phase 3 study, known as ICARIA-MM, enrolled 307 patients with relapsed/refractory multiple myeloma across 96 centers spanning 24 countries. All study participants received two or more prior anti-myeloma therapies, including at least two consecutive cycles of lenalidomide and a proteasome inhibitor given alone or in combination. During the trial, isatuximab was administered through an intravenous infusion at a dose of 10mg/kg once weekly for four weeks, then every other week for 28-day cycles in combination with standard doses of pomalidomide and dexamethasone for the duration of treatment. The safety profile was evaluated as a secondary endpoint.